Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders

Woo, Yu Ri; Hwang, Sung Ho; Jeong, Sungmoon; Cho, Dae Ho; Park, Hyun Jeong

doi:10.3390/ijms18020316

Cited by 4 publications

(4 citation statements)

References 35 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important aspect is the EP itself. Piérard-Franchimont and Piérard [48] related the disrupted functionality of the EP with alopecia areata, [49,50]. The present study showed how CK15 and TE protein expression was modified in the EP of areas with AGA, suggesting that there is involvement of different components of scalp tissue with alopecia, with consequences for cellular homeostasis.…”

Section: Discussionsupporting

confidence: 54%

Decreased expression of cytokeratin 15 and tropoelastin in men with androgenetic alopecia and its relationship with increased expression of p15/p16

et al. 2020

View full text Add to dashboard Cite

IntroductionAndrogenetic alopecia (AGA) or male pattern baldness is a polygenic disease with a high prevalence in the Caucasian population, with psychosocial implications. However, the molecular mechanisms involved are unknown. The aim of this study was to assess the possible changes in protein expression of cytokeratin 15 (CK15), tropoelastin (TE) and cellular senescence markers (p15/p16) in AGA patients.Material and methodsAn observational, analytical and prospective cohort study was performed in 57 men with AGA (42.31 ±3.01 years). Two tissue biopsies were taken: the control area (C) and the alopecia area (A). Cell viability was assessed using scalp explants from the patients, maintaining explants long term (90 days). Protein expression analysis was performed by immunohistochemistry by detecting antigen-antibody reactions (avidin-biotin complex).Resultshe results showed a significantly higher percentage of dead cells in area A (17.00 ±1.09% C vs. 28.50 ±1.41% A, *p < 0.05). The area affected by alopecia showed significantly lower CK15 and TE protein expression in hair follicles, sebaceous glands and epidermis (*p < 0.05). Expression of the senescence marker p15/p16 was significantly higher in hair follicles, hair bulbs and the epidermis (*p < 0.05).ConclusionsThe results suggest that patients with AGA suffer tissue damage that affects different components of hair follicle stem cells as well as the extracellular matrix itself.

show abstract

Section: Discussionsupporting

confidence: 54%

Decreased expression of cytokeratin 15 and tropoelastin in men with androgenetic alopecia and its relationship with increased expression of p15/p16

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The level of Erdr1 was significantly lower in severe type of the disease than in mild/moderate one, however, the level of IL-18 is significantly higher in severe form of AA than in mild/moderate form. In contrast, there is a study reported that the severity of AA was not significantly correlated with the intensity of Erdr1 expression 18 . Also, another study found nonsignificant differences in IL-18 levels between the patients with extensive and localized AA 8 .…”

Section: Discussionmentioning

confidence: 80%

“…Woo et al 18 proposed that down regulation of Erdr1 may be involved in the inflammatory cascade in AA and they explained the significant downregulation of Erdr1 expression in AA by these points: First, cellmediated immunity play the principal role in hair loss disorders 19 . Moreover, T helper 1 cytokines in AA are implicated in the dysregulation of the hair follicle's immune homeostasis 20 .…”

Section: Discussionmentioning

confidence: 99%

Role of Erythroid Differentiation Regulator 1 (Erdr1) in Alopecia Areata

Tabl

Sorour

2019

Egyptian Journal of Medical Microbiology

View full text Add to dashboard Cite

Background: Several markers have been discovered and validated for alopecia areata (AA). However, their exact roles have not yet been fully studied. Erythroid differentiation regulator 1 (Erdr1), an IL-18-regulated factor, is one of these novel markers. Objectives: This work aimed to study the role of Erdr1 in AA and to correlate its skin mRNA expression level with serum level of IL-18. Methodology: Twenty-five AA patients and 10 healthy control subjects were included in the study. The level of skin expression of Erdr1 mRNA was measured by reverse transcriptase-polymerase chain reaction (RT-PCR). Serum IL-18 level was measured by enzyme-linked immunosorbent assay (ELISA). Results: The level of skin expression of Erdr1 mRNA was 0.214 fold lower in AA patients compared to control group, it was (in log relative unit) 6.61 ± 0.188 Vs 7.17 ± 0.193 for AA patients Vs control group respectively. The level of IL-18 (in pg/ml) in serum was higher in AA patients compared to control group, it was 245.1 ± 51.8 Vs 96.8 ± 38.1 for AA patients Vs control group respectively. In severe type of the disease, there was lower skin level of Erdr1 mRNA and higher serum IL-18 level than in moderate one. There was a significant negative correlation between IL-18 serum level and Erdr1 mRNA skin expression level among patients group (r= -0.786, P <0.001). In conclusion: Erdr1 has a role in the pathogenesis of AA and can be used as a marker for diagnosis.

show abstract

“…However, the sequence of human Erdr1 was not identified in the present study; the sequence of human Erdr1 will be analyzed in future studies. Our recent study reported that Erdr1 is a potential therapeutic agent for inflammatory skin diseases including psoriasis ( 25 ), rosacea ( 26 ) and hair loss disorders ( 39 ); therefore, we hypothesized in the present study that Erdr1 may also promote wound healing.…”

Section: Discussionmentioning

confidence: 95%

Erythroid differentiation regulator 1 promotes wound healing by inducing the production of C‑C motif chemokine ligand 2 via the activation of MAP kinases in vitro and in vivo

et al. 2020

View full text Add to dashboard Cite

The erythroid differentiation regulator 1 (Erdr1) protein has been studied for its role in various inflammatory skin diseases, including skin cancer, actinic keratosis and psoriasis. However, the therapeutic effects of Erdr1 on wound repair and its underlying mechanisms remain unknown. The present study aimed to investigate the effects of Erdr1 on wound healing in vitro and in vivo . The results demonstrated that treatment with recombinant Erdr1 enhanced wound healing in vivo and in vitro . In addition, Erdr1 increased the proliferation and migration of human dermal fibroblasts (HDFs). Notably, Erdr1 significantly induced the production of the chemoattractant C-C motif chemokine ligand 2 (CCL2) and recruited immune cells involved in wound healing. Treatment with recombinant Erdr1 induced the activation of the ERK1/1, p38 and JNK1/2 mitogen-activated protein (MAP) kinases. Treatment with specific inhibitors for MAP kinase inhibitors markedly suppressed cell proliferation and migration, and inhibited the production of CCL2 in HDFs. Furthermore, the inhibition of CCL2 with a neutralizing antibody significantly suppressed the recombinant Erdr1-induced proliferation and migration of HDFs. The wound healing activity of Erdr1 was comparable to that of epidermal growth factor. Taken together, these results demonstrated that Erdr1 promoted the proliferation and migration of HDFs and exhibited potent wound healing properties mediated by CCL2. Therefore, the results of the present study suggested that Erdr1 may be a potential therapeutic target for promoting wound healing.

show abstract

Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders

Cited by 4 publications

References 35 publications

Decreased expression of cytokeratin 15 and tropoelastin in men with androgenetic alopecia and its relationship with increased expression of p15/p16

Decreased expression of cytokeratin 15 and tropoelastin in men with androgenetic alopecia and its relationship with increased expression of p15/p16

Role of Erythroid Differentiation Regulator 1 (Erdr1) in Alopecia Areata

Erythroid differentiation regulator 1 promotes wound healing by inducing the production of C‑C motif chemokine ligand 2 via the activation of MAP kinases in vitro and in vivo

Contact Info

Product

Resources

About